Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
It has been suggested that, after an initial “loading dose” for a period of time, abiraterone acetate could potentially be used to treat metastatic, castration-resistant prostate cancer (mCRPC) at a much lower daily maintenance dose than that currently approved.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, low-dose, maintenance | 10 Comments »
In an utterly unsurprising announcement from the UK, the National Institute for Clincial Excellence (NICE) has issued draft guidance in which it refuses to cover the proposed cost of abiraterone actetate.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cost, NICE, UK, Zytiga | 6 Comments »
According to a report in today’s Daily Telegraph, the UK’s National Institute for Health and Clinical Excellence (NICE) has determined that “cabazitaxel would not be a cost effective use of limited NHS resources” for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Management, Treatment | Tagged: abiraterone, cabazitaxel, cost, NICE, UK | 2 Comments »
Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, approval, Europe, Zytiga | Leave a Comment »
A recent review article concludes with the statement, “5α-reductase inhibition does seem to have beneficial effects on prostate cancer incidence, and the role of [5α-reductase inhibitors (5-ARIs)] in combination with other agents should be further evaluated for the treatment of [castration-resistant prostate cancer (CRPC)].”
Filed under: Drugs in development, Management, Treatment | Tagged: 5-ARI, 5α-reductase, abiraterone, inhibitor | 5 Comments »
A new paper in Clinical Cancer Research indicates that at least some men will have a short-term bone scan “flare” as a consequence of initiation of treatment with abiraterone acetate. The clinical significance of this flare is still to be fully evaluated.
Filed under: Management, Treatment | Tagged: abiraterone, bone scan, flare | 4 Comments »
As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, circulating tumor cell, CTC, survival, Zytiga | Leave a Comment »
A story on the Bloomberg.com web site gives information about a patient with castration-resistant prostate cancer (CRPC) who has had a zero-level PSA for 40 months since starting on a clinical trial of abiraterone actetate in early 2008.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, CRPC, orteronel, survival, TAK-700 | 3 Comments »
An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cabazitaxel, castration-resistant prostate cancer, CRPC | 12 Comments »
We have already noted the FDA’s approval of abiraterone acetate. However, there are some interesting details that are worthy of note.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, approval, survival, Zytiga | 2 Comments »
The FDA has today approved abiraterone acetate (Zytiga™) for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. A full media release is already available on the Centocor Ortho Biotech web site. There is another media release on the FDA web [...]
Filed under: Drugs in development, Management | Tagged: abiraterone | 4 Comments »
As we get closer to the annual meeting of the American Society of Clinical Oncology (ASCO) — to be held at the beginning of June — the investor community is beginning its annual frenzy of speculation about exactly what new information will be presented at the meeting about development stage and marketed drugs.
Filed under: Drugs in development | Tagged: abiraterone, ASCO, investment, MDV3100 | 1 Comment »
Patients and others with a strong interest in understanding the ways in which new drugs like abiraterone acetate and MDV3100 are likely to change the way we treat advanced forms of prostate cancer might be interested in a webcast based on a satellite symposium held at the recent Genitourinary Cancers Symposium in Orlando.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, CRPC, MDV3100 | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site